Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 38

Results For "CEP"

1786 News Found

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year


Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
News | January 30, 2026

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio


Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
News | January 29, 2026

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites


Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research
Clinical Trials | January 29, 2026

Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research

The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results


Eastman & Kolmar Korea join forces to deliver biodegradable beauty breakthroughs
R&D | January 28, 2026

Eastman & Kolmar Korea join forces to deliver biodegradable beauty breakthroughs

The collaboration will center on expanding access to Eastman’s Esmeri technology


Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Drug Approval | January 24, 2026

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India


Lupin receives highest ESG rating from CDP for climate change and water security
Sustainability | January 24, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability


Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
News | January 23, 2026

Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025